Novo Nordisk A/S $NVO Shares Sold by RWA Wealth Partners LLC

RWA Wealth Partners LLC trimmed its position in shares of Novo Nordisk A/S (NYSE:NVO) by 19.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 193,931 shares of the company’s stock after selling 48,129 shares during the quarter. RWA Wealth Partners LLC’s holdings in Novo Nordisk A/S were worth $10,761,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in NVO. Jennison Associates LLC boosted its stake in shares of Novo Nordisk A/S by 0.3% in the second quarter. Jennison Associates LLC now owns 18,885,343 shares of the company’s stock valued at $1,303,466,000 after buying an additional 63,341 shares in the last quarter. Loomis Sayles & Co. L P lifted its holdings in shares of Novo Nordisk A/S by 1.5% in the second quarter. Loomis Sayles & Co. L P now owns 12,576,031 shares of the company’s stock valued at $867,998,000 after purchasing an additional 187,789 shares in the last quarter. Folketrygdfondet grew its position in shares of Novo Nordisk A/S by 1.2% in the third quarter. Folketrygdfondet now owns 10,211,913 shares of the company’s stock valued at $566,659,000 after purchasing an additional 117,370 shares during the last quarter. Sustainable Growth Advisers LP increased its stake in shares of Novo Nordisk A/S by 11.7% during the 2nd quarter. Sustainable Growth Advisers LP now owns 6,192,636 shares of the company’s stock worth $427,416,000 after purchasing an additional 649,390 shares in the last quarter. Finally, State Street Corp raised its position in shares of Novo Nordisk A/S by 0.8% during the 2nd quarter. State Street Corp now owns 6,047,683 shares of the company’s stock worth $418,231,000 after purchasing an additional 47,430 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on NVO shares. Jefferies Financial Group upgraded Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a report on Thursday, February 12th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a research note on Thursday, January 22nd. BMO Capital Markets reissued a “market perform” rating on shares of Novo Nordisk A/S in a research note on Thursday, February 5th. CICC Research began coverage on shares of Novo Nordisk A/S in a report on Friday, January 9th. They issued an “outperform” rating and a $73.50 target price on the stock. Finally, Weiss Ratings upgraded shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, February 5th. Six equities research analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Hold” and a consensus price target of $56.07.

Novo Nordisk A/S Stock Down 2.5%

NVO opened at $38.64 on Wednesday. Novo Nordisk A/S has a 12 month low of $38.36 and a 12 month high of $93.80. The business has a 50-day moving average of $53.35 and a two-hundred day moving average of $53.14. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. The stock has a market capitalization of $172.52 billion, a price-to-earnings ratio of 11.13 and a beta of 0.67.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The business had revenue of $12.43 billion for the quarter, compared to analysts’ expectations of $11.97 billion. On average, research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Dividend Announcement

The business also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be paid a dividend of $1.2751 per share. The ex-dividend date of this dividend is Monday, March 30th. This represents a dividend yield of 541.0%. Novo Nordisk A/S’s payout ratio is currently 23.63%.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Positive pipeline readout — a China Phase‑2 trial of triple‑agonist UBT251 (GLP‑1/GIP/glucagon) showed up to 19.7% mean weight loss at 24 weeks, highlighting diversification beyond semaglutide and a potential growth pillar if further trials confirm efficacy. Read More.
• Neutral Sentiment: Strategic/operational profiling — a ResearchAndMarkets/enterprise‑tech profile highlights Novo’s digital transformation and tech initiatives; useful context for long‑term efficiency but unlikely to move stock short‑term. Read More.
• Negative Sentiment: Phase‑III setback — CagriSema failed to demonstrate non‑inferiority to Lilly’s tirzepatide in REDEFINE‑4, directly triggering investor panic about Novo’s ability to defend obesity market share. Read More.
• Negative Sentiment: Price cuts announced — Novo said it will cut U.S. list prices for Ozempic and Wegovy (up to ~50% for Wegovy) starting 2027 to improve access, a move the market views as margin/revenue negative given the drugs’ current sales scale. Read More.
• Negative Sentiment: Analyst downgrades & sell‑side reassessment — Deutsche Bank, Kepler and others have cut ratings/targets after the trial news, accelerating selling and downward re‑pricing of NVO. Read More.
• Negative Sentiment: Legal/investor scrutiny — law firms have initiated investor‑suit outreach, adding headline risk and potential distraction. Read More.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.